Exercise trial for Exosomes

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Exosomes+2 More
Resistance Exercise - Procedure
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

The proposed study aims to shed light on the function/importance/relevance of exercise-induced changes in exosomes to connective tissues. Exosomes are known to increase robustly in response to exercise. We have previously shown that serum isolated from subjects after they lift heavy weights increases human engineered ligament collagen content and mechanics more than serum from before they lift weight. Further, we showed that exercise-induced changes in hormones could not explain the change in ligament structure or function. These data indicate that there is a significant gap in our understanding of muscle-connective tissue crosstalk. To address this gap, the current proposal seeks to: i) isolate and sequence exosomal RNA (long non-coding, miR, and mRNA) and ii) determine whether exosomes isolated from serum after exercise increase engineered ligament mechanics and collagen content.

Eligible Conditions
  • Exercise
  • Exosomes
  • Connective Tissue

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 15 min post-exercise

15 min post-exercise
Ligaments
Exosomal RNA
Ligaments

Trial Safety

Trial Design

1 Treatment Group

Exercise trial
1 of 1

Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: Exercise trial · No Placebo Group · N/A

Exercise trial
Procedure
Experimental Group · 1 Intervention: Resistance Exercise · Intervention Types: Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Resistance Exercise
2017
Completed Phase 4
~880

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 15 min post-exercise

Who is running the clinical trial?

University of California, DavisLead Sponsor
838 Previous Clinical Trials
5,002,876 Total Patients Enrolled
Keith Baar, PhDPrincipal InvestigatorUniversity of California, Davis
4 Previous Clinical Trials
102 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: November 25th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.